{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:59:00Z","timestamp":1770235140031,"version":"3.49.0"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adult T-cell leukemia\u2013lymphoma is defined as peripheral T-cell lymphoma caused by the human T-cell leukemia virus type I. Adult T-cell leukemia\u2013lymphoma is classified into indolent (favorable chronic or smoldering) or aggressive (acute, lymphoma or unfavorable chronic) types. This review discusses the therapeutic developments for patients with adult T-cell leukemia\u2013lymphoma and unmet issues in treating adult T-cell leukemia\u2013lymphoma. For indolent adult T-cell leukemia\u2013lymphoma, a watchful waiting strategy is recommended until the disease progresses to aggressive adult T-cell leukemia\u2013lymphoma. For aggressive adult T-cell leukemia\u2013lymphoma, multi-agent chemotherapy with or without allogeneic hematopoietic stem cell transplantation has been recommended. However, many patients with adult T-cell leukemia\u2013lymphoma relapse, and their prognosis is poor. Recently, novel agents, including mogamulizumab, lenalidomide, brentuximab vedotin, tucidinostat and valemetostat, have been approved for patients with relapsed or refractory aggressive adult T-cell leukemia\u2013lymphoma, and the combination of mogamulizumab with multi-agent chemotherapy or brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone has been approved for patients with untreated aggressive adult T-cell leukemia\u2013lymphoma in Japan. Importantly, the aging of patients with adult T-cell leukemia\u2013lymphoma has recently been reported, and no standard of care for elderly patients with adult T-cell leukemia\u2013lymphoma has been established. New evidence must be obtained from prospective clinical trials to improve the prognosis of patients with adult T-cell leukemia\u2013lymphoma.<\/jats:p>","DOI":"10.1093\/jjco\/hyad108","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:20:27Z","timestamp":1692343227000},"page":"1104-1111","source":"Crossref","is-referenced-by-count":8,"title":["An update on the developments in the treatment of adult T-cell leukemia\u2013lymphoma: current knowledge and future perspective"],"prefix":"10.1093","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-2920","authenticated-orcid":false,"given":"Junya","family":"Makiyama","sequence":"first","affiliation":[{"name":"Sasebo City General Hospital Department of Hematology, , Sasebo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Kagoshima University Department of Hematology and Rheumatology, , Kagoshima , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Hematology, , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Hematology Oncology, , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"National Hospital Organization Nagoya Medical Center Clinical Research Center, , Nagoya , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"2023120714395818200_ref1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"2023120714395818200_ref2","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023120714395818200_ref3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/aid.1993.9.381","article-title":"An HTLV-I vaccine: Why, how, for whom?","volume":"9","author":"The","year":"1993","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023120714395818200_ref4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 infection and ATL in Japan: an update","volume":"11","author":"Iwanaga","year":"2020","journal-title":"Front Microbiol"},{"key":"2023120714395818200_ref5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.23181","article-title":"Current prevalence of HTLV-1 in Japan as determined by screening of blood donors","volume":"84","author":"Satake","year":"2012","journal-title":"J Med Virol"},{"key":"2023120714395818200_ref6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S1473-3099(16)30252-3","article-title":"Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis","volume":"16","author":"Satake","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2023120714395818200_ref7","doi-asserted-by":"crossref","first-page":"e28606","DOI":"10.1002\/jmv.28606","article-title":"Lower prevalence of anti-HTLV-1 as expected by previous models among first-time blood donors in Japan","volume":"95","author":"Satake","year":"2023","journal-title":"J Med Virol"},{"key":"2023120714395818200_ref8","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2023120714395818200_ref9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10428199309087005","article-title":"Autopsy findings in 47 cases of adult T-cell leukemia\/lymphoma in Miyazaki prefecture","volume":"11","author":"Suzumiya","year":"1993","journal-title":"Japan Leuk Lymphoma"},{"key":"2023120714395818200_ref10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02983215","article-title":"Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)","volume":"77","author":"Tsukasaki","year":"2003","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref12","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12185-018-02588-5","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma","volume":"109","author":"Tsukasaki","year":"2019","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref16","first-page":"221","volume-title":"Adult T-cell Leukaemia","author":"Shimoyama","year":"1994"},{"key":"2023120714395818200_ref17","doi-asserted-by":"crossref","first-page":"e0010807","DOI":"10.1371\/journal.pntd.0010807","article-title":"The importance of the clinical classification of adult T-cell leukemia\/lymphoma (ATLL) in the prognosis","volume":"16","author":"Oliveira","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2023120714395818200_ref18","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica"},{"key":"2023120714395818200_ref20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-01-757542","article-title":"Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma","volume":"130","author":"Katsuya","year":"2017","journal-title":"Blood"},{"key":"2023120714395818200_ref22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-022-03473-y","article-title":"Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study","volume":"117","author":"Imaizumi","year":"2023","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref23","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"key":"2023120714395818200_ref24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"key":"2023120714395818200_ref25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients","volume":"113","author":"Matutes","year":"2001","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.thj.6200195","article-title":"A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma","volume":"3","author":"Hermine","year":"2002","journal-title":"Hematol J"},{"key":"2023120714395818200_ref27","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref28","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1200\/JCO.2010.32.1380","article-title":"Is zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma?","volume":"28","author":"Ishitsuka","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/10428194.2021.1984455","article-title":"An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia\/lymphoma","volume":"63","author":"Malpica","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2023120714395818200_ref30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.1988.6.1.128","article-title":"Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin\u2019s lymphoma treated with VEPA or VEPA-M","volume":"6","author":"Shimoyama","year":"1988","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jjco\/hyr168","article-title":"Lymphoma study group of JCOG","volume":"42","author":"Tsukasaki","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"2023120714395818200_ref32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.15950","article-title":"Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801","volume":"186","author":"Toyoda","year":"2019","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref33","first-page":"100492","article-title":"Adult T-cell leukemia and lymphoma in French Guiana: a retrospective analysis with real-life data from 2009 to 2019","volume":"21","author":"Abdelmoumen","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2023120714395818200_ref34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/GO.21.00084","article-title":"Real-world data on adult T-cell leukemia\/lymphoma in Latin America: a study from the Grupo de Estudio Latinoamericano de Linfoproliferativos","volume":"7","author":"Malpica","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2023120714395818200_ref35","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fmicb.2019.02235","article-title":"Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"Front Microbiol"},{"key":"2023120714395818200_ref36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s44228-023-00032-y","article-title":"Outcome of stem cell transplantation in HTLV-1-associated north American adult T-cell leukemia\/lymphoma","volume":"5","author":"Bazarbachi","year":"2023","journal-title":"Clin Hematol Int"},{"key":"2023120714395818200_ref37","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","article-title":"Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study","volume":"5","author":"Ito","year":"2021","journal-title":"Blood Adv"},{"key":"2023120714395818200_ref38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bmt.1701533","article-title":"Poor outcome of autologous stem cell transplantation for adult T cell leukemia\/lymphoma: a case report and review of the literature","volume":"23","author":"Tsukasaki","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2023120714395818200_ref39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41409-021-01412-9","article-title":"Long-term follow-up of patients with ATL after autologous stem cell transplantation","volume":"57","author":"Utsunomiya","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2023120714395818200_ref40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2023120714395818200_ref41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2141.2003.04054.x","article-title":"Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia\/lymphoma","volume":"120","author":"Kami","year":"2003","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"2023120714395818200_ref43","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2004-11-4193","article-title":"Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma","volume":"105","author":"Okamura","year":"2005","journal-title":"Blood"},{"key":"2023120714395818200_ref44","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"key":"2023120714395818200_ref45","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1111\/cas.15097","article-title":"Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012-2013","volume":"112","author":"Ito","year":"2021","journal-title":"Cancer Sci"},{"key":"2023120714395818200_ref46","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"key":"2023120714395818200_ref47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-012-1177-8","article-title":"Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute","volume":"96","author":"Nakamura","year":"2012","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12185-013-1307-y","article-title":"Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia\/lymphoma: a retrospective analysis of the Nagasaki transplantation network","volume":"97","author":"Fukushima","year":"2013","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41409-023-01919-3","article-title":"Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study","volume":"58","author":"Tokunaga","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2023120714395818200_ref50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/hematology.2019001323","article-title":"How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide","volume":"2019","author":"McCurdy","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023120714395818200_ref51","doi-asserted-by":"crossref","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2023120714395818200_ref52","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"2023120714395818200_ref53","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2023120714395818200_ref54","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem"},{"key":"2023120714395818200_ref55","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2023120714395818200_ref56","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref57","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"key":"2023120714395818200_ref58","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref60","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref61","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"2023120714395818200_ref62","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","article-title":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","volume":"107","author":"Tanaka","year":"2022","journal-title":"Haematologica"},{"key":"2023120714395818200_ref63","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref64","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref65","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023120714395818200_ref66","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/cas.15431","article-title":"Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma: phase IIb results","volume":"113","author":"Utsunomiya","year":"2022","journal-title":"Cancer Sci"},{"key":"2023120714395818200_ref67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"2023120714395818200_ref68","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"2023120714395818200_ref69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm, phase 2 trial of valemetostat in relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"2023120714395818200_ref70","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12185-014-1665-0","article-title":"Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience","volume":"100","author":"Makiyama","year":"2014","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12185-019-02769-w","article-title":"Treatment of aggressive adult T-cell leukemia\/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area","volume":"111","author":"Nakamura","year":"2020","journal-title":"Int J Hematol"},{"key":"2023120714395818200_ref72","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br J Haematol"},{"key":"2023120714395818200_ref73","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1182\/blood-2021-151937","article-title":"CHOP plus sequential mogamulizumab as first-line therapy for untreated adult T-cell leukemia-lymphoma","volume":"138","author":"Tanimoto","year":"2021","journal-title":"Blood"},{"key":"2023120714395818200_ref74","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2023.41.16_suppl.7504","article-title":"A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia\/lymphoma","volume":"41","author":"Choi","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023120714395818200_ref75","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2023120714395818200_ref76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-020-00561-w","article-title":"Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma","volume":"15","author":"Shea","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"2023120714395818200_ref77","doi-asserted-by":"crossref","first-page":"100169","DOI":"10.1016\/j.modpat.2023.100169","article-title":"A comprehensive study of the immunophenotype and its clinicopathological significance in adult T-cell leukemia\/lymphoma","volume":"36","author":"Tamaki","year":"2023","journal-title":"Mod Pathol"},{"key":"2023120714395818200_ref78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2023120714395818200_ref79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase 3 study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"2023120714395818200_ref80","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-18-0268","article-title":"CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals","volume":"24","author":"Nakashima","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023120714395818200_ref81","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/cas.15706","article-title":"The oncogenic driving force of CD30 signaling-induced chromosomal instability in adult T-cell leukemia\/lymphoma","volume":"114","author":"Nakashima","year":"2023","journal-title":"Cancer Sci"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/12\/1104\/54060512\/hyad108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/12\/1104\/54060512\/hyad108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:29:17Z","timestamp":1701970157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/12\/1104\/7244539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":81,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad108","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,8,17]]}}}